Aldeyra Therapeutics, Inc. (ALDX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Aldeyra Therapeutics, Inc. (ALDX) is down 60.4% since the beginning of the year. At $2 per share, ALDX is trading 66.8% below its 52-week high of $6. Investors who bought $1,000 worth of ALDX shares 5 years ago would now be looking at an investment worth $183.

Aldeyra Therapeutics, Inc. (ALDX) has returned -60.42% so far this year and -32.79% over the past 12 months. Over the last ten years, ALDX has returned -9.06% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since May 2, 2014, ALDX's average daily return is +0.15%, while the average monthly return is +2.39%. At this rate, an investment would double in approximately 2.4 years.

Historically, 49% of months were positive and 51% were negative. The best month was Jun 2025 with a return of +78.1%, while the worst month was Oct 2023 at -74.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ALDX closed higher 46% of trading days. The best single day was Sep 14, 2017 with a return of +70.1%, while the worst single day was Apr 3, 2025 at -73.3%.

Aldeyra Therapeutics, Inc. has an annualized alpha of 22.89%, beta of 1.28, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since May 02, 2014.

• This stock participated in 190.86% of S&P 500 Index downside but only 104.61% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ALDX ranks 36 for risk / return — below 36% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Aldeyra Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aldeyra Therapeutics, Inc. was 91.65%, occurring on Mar 17, 2026. The portfolio has not yet recovered.

The current Aldeyra Therapeutics, Inc. drawdown is 86.20%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Aldeyra Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Aldeyra Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.